Side effects include:
Extrapyramidal reactions (e.g., Parkinson-like symptoms, dystonia, akathisia, tardive dyskinesia), drowsiness, dizziness, skin reactions or rash, dry mouth, orthostatic hypotension, amenorrhea, galactorrhea, weight gain.     
The most frequently reported side effects included drowsiness, sedation, dry mouth, and nasal stuffiness.
Very common (10% or more): Mild leukopenia (up to 30%)Common (1% to 10%): Agranulocytosis, leukopenia, eosinophilia, hemolytic anemia, aplastic anemia, thrombocytopenia purpura, pancytopeniaUncommon (0.1% to 1%): Purpura, leukocytosis, coagulation defects
Acute dystonia and/or dyskinesia typically were transitory, occurring more frequently in children and young adults within the first 4 days of treatment or after dose changes.Akathisia usually occurred after patients were given large initial doses.Autonomic dysfunction occurred as a symptom of neuroleptic malignant syndrome.Convulsive seizures have occurred more frequently in patients with a history of seizures and/or with EEG abnormalities.Momentary fainting occurred most commonly in patients after the first injection, with a lower frequency of occurrence in subsequent injections; patients given oral formulations rarely fainted after the initial dose.Parkinsonism more commonly occurred in adults and elderly patients after weeks to months of treatment.Sedation and somnolence occurred more frequently at the start of treatment.
Common (1% to 10%): Hypertonia, tardive dyskinesia, tardive dystonia, extrapyramidal syndrome, akathisia, parkinsonism, motor restlessness, drowsiness, convulsion/convulsive seizures (petit mal and grand mal), lowering of the seizure threshold, acute dyskinesia or dystoniaUncommon (0.1% to 1%): Cerebral edema, epileptic fits, neuroleptic malignant syndrome, myasthenia gravis, abnormality of cerebrospinal fluid proteinsFrequency not reported: Lethargy, akinesia, hyperkinesia, autonomic dysfunction, tremor, drooling, pill rolling motion, cogwheel rigidity, shuffling gait, rhythmical involuntary movements of the tongue/face/mouth/jaw, involuntary movements of the extremities, fine vermicular movements of the tongue, dizziness, headache, momentary fainting, pseudo-parkinsonism, mask-like faciesPostmarketing reports: Cerebrovascular adverse events
Common (1% to 10%): Dry mouth, constipation, nausea, obstipation, adynamic ileus, atonic colonUncommon (0.1% to 1%): Paralytic ileusPostmarketing reports: Ischemic colitis, intestinal perforation/fatal intestinal perforation, gastrointestinal (GI) necrosis/fatal GI necrosis, intestinal obstruction, tongue protrusion, difficulty swallowing, necrotizing colitis/fatal necrotizing colitis
Common (1% to 10%): Anxiety, mental confusion, agitation, excitement, aggravation of schizophrenic symptomsUncommon (0.1% to 1%): Nightmares, dysphoria, catatonic excitement, mental dulling/slowingRare (0.01% to 0.1%): Psychotic symptoms, catatonic-like statesFrequency not reported: Insomnia, altered mood, altered consciousness
Altered consciousness occurred as a symptom of neuroleptic malignant syndrome.
Accommodation disorder was related to anticholinergic effects of this drug.Eye deposits occurred in the anterior segment of the eye from drug accumulation; however, the deposits usually did not have impact on sight.
Common (1% to 10%): Blurred vision, photophobia, corneal/eye deposits, miosis and mydriasisUncommon (0.1% to 1%): Optic atrophy, lens opacities, pigmentary retinopathy, precipitation/aggravation of narrow angle glaucomaFrequency not reported: Oculogyric crisis, ocular changes, accommodation disorder
Lactation and breast engorgement in female patients occurred with large doses.Urinary retention was linked to anticholinergic effects of this drug.
Common (1% to 10%): Urinary retention/hesitancy, priapism, ejaculation disorders/impotenceUncommon (0.1% to 1%): Amenorrhea, incontinence, lactation and moderate breast engorgement (female patients)Frequency not reported: Galactorrhea, oligomenorrhea, erectile dysfunction, female sexual arousal disorder
Common (1% to 10%): Contact dermatitis, photosensitivity/photosensitivity reaction, urticarial/maculopapular/petechial or edematous reactionUncommon (0.1% to 1%): Skin pigmentation, exfoliative dermatitis, toxic epidermal necrolysisFrequency not reported: Allergic dermatitis, skin rashesPostmarketing reports: Angioneurotic edema
Common (1% to 10%): Impaired glucose tolerance, hyperglycemia, weight gainUncommon (0.1% to 1%): Hypoglycemia, water retentionPostmarketing reports: Hypertriglyceridemia, hyponatremia, increased appetite
Cardiac arrest may be related to dose as well as preexisting conditions (e.g., cardiac disease, old age, hypokalemia, concurrent tricyclic antidepressants).Hypertensive crisis occurred after abrupt withdrawal of treatment.Orthostatic hypotension occurred more frequently in elderly and/or volume depleted patients, and was more likely to occur with IM administration.Sudden cardiac death may be related to causes of cardiac origin.
Common (1% to 10%): Orthostatic/postural hypotension, ECG changes (electrocardiogram QT prolongation, ST depression, U-Wave and T-Wave changes)Uncommon (0.1% to 1%): Arrhythmias, hypertensive crisis, AV block, ventricular tachycardia/tachycardia, QT prolongation and fibrillation, edema, labile blood pressureFrequency not reported: Ventricular fibrillation, Torsade de pointes, cardiac arrest, sudden cardiac death, profound hypotension, peripheral edema, venous embolism, deep vein thrombosis, cardiac arrhythmias (including ventricular and atrial arrhythmias)
Common (1% to 10%): Hypothalamic effects, hyperprolactinemia/elevated prolactin levelsUncommon (0.1% to 1%): Gynecomastia, profuse sweating, false positive pregnancy tests, inappropriate antidiuretic hormone secretion
Hyperthermia occurred as a symptom of neuroleptic malignant syndrome.Mild fevers have occurred in patient who received large doses intramuscularly.Sudden death may be related to causes of cardiac origin, asphyxia, convulsions, or hyperpyrexia.
Common (1% to 10%): Paradoxical reactions, impaired thermoregulation/temperature regulation disorderUncommon (0.1% to 1%): Hyperthermia, hypothermia, malignant hyperpyrexiaFrequency not reported: Sudden death, jitteriness, neonatal drug withdrawal syndrome
Common (1% to 10%): Nasal congestion/stuffiness, respiratory depressionUncommon (0.1% to 1%): DyspneaFrequency not reported: Bronchospasm, pulmonary embolism/fatal pulmonary embolismPostmarketing reports: Asthma, laryngeal edema, throat tightness, asphyxia (failure of the cough reflex)
Contact sensitization has occurred in individuals who frequently handled this drug.
Common (1% to 10%): Injection site pain, injection abscessUncommon (0.1% to 1%): Contact skin sensitization
Common (1% to 10%): Positive systemic lupus erythematosus (SLE) cells, antinuclear antibody (ANA) positive/raised ANA titer
Common (1% to 10%): Cholestatic jaundiceUncommon (0.1% to 1%): Liver injury, fatal liver injury, cholestatic/hepatocellular or mixed liver injuryFrequency not reported: Progressive hepatic fibrosis
Uncommon (0.1% to 1%): Elevated creatine phosphokinase, muscular rigidity/rigidity, myoglobinuria/rhabdomyolysisRare (0.01% to 0.1%): Systemic lupus erythematosus Frequency not reported: Torticollis, trismusPostmarketing reports: Prolonged, abnormal muscle contractions, neck muscle spasms
Elevated creatine phosphokinase, muscular rigidity, and myoglobinuria/rhabdomyolysis are symptoms of neuroleptic malignant syndrome.Rigidity occurred as a symptom of neuroleptic malignant syndrome.
Uncommon (0.1% to 1%): Glycosuria, acute renal failure
Uncommon (0.1% to 1%): Severe allergic reactions/allergic reactionsRare (0.01% to 0.1%): Anaphylactic/anaphylactoid reactionsFrequency not reported: Angioedema